Global Cell and Gene Therapy Biomanufacturing Market
Description
MARKET SCOPE:
The global cell and gene therapy biomanufacturing market is projected to grow significantly, registering a CAGR of 11.3% during the forecast period (2024 – 2032).
Cell and gene therapy biomanufacturing involves the creation of therapeutic products through the manipulation of cells or genes, addressing various diseases. In cell therapy, live and functional cells are administered to patients to restore, repair, or enhance damaged tissues or organs. Conversely, gene therapy focuses on altering genetic material within a patient's cells to prevent or treat diseases. The biomanufacturing process for cell and gene therapies is intricate and highly regulated, intending to produce these advanced therapeutic products consistently and safely at a scale suitable for clinical and commercial applications. The initial step includes isolating cells from the patient or another source, followed by their expansion in a controlled culture environment. This cultivation phase aims to provide optimal conditions for cell growth while preserving the desired characteristics of the therapeutic cells. The overall objective is to adhere to rigorous quality control measures throughout the biomanufacturing process, ensuring the reliability, safety, and effectiveness of the final cell and gene therapies. The field of cell and gene therapy biomanufacturing continues to evolve, integrating advances in automation, process optimization, and standardization to enhance efficiency and scalability, bringing these innovative therapies closer to widespread clinical implementation.
MARKET OVERVIEW:
Driver: Increasing cancer diseases worldwide is expected to boost the market growth.
The increasing prevalence of cancer and other targeted diseases, coupled with rising research and development investments in pharmaceutical companies, is propelling the expansion of the market. A revised version of GLOBOCAN 2020 by the International Agency for Research on Cancer (IARC) indicates a global cancer burden of 19.3 million cases and 10 million cancer-related deaths in 2020. A recent study predicts that over the next five years, more than 50 million people will be diagnosed with cancer. Factors such as aging populations and socioeconomic risk factors are significant contributors to the rising incidence of cancer worldwide. Notably, breast cancer represents one in every four cancers diagnosed in women globally, surpassing lung cancer as the most commonly diagnosed cancer worldwide, particularly prevalent in low- and middle-income nations.
Given the complexity of cancer, cell and gene therapy emerges as a promising field for cancer treatment. Various gene therapy treatment approaches, including immunotherapy, gene transfer, and oncolytic virotherapy, offer innovative solutions. As the incidence of cancer continues to rise, the reliance on gene therapy is expected to grow, thereby stimulating market growth. The evolving landscape of cancer treatment presents substantial opportunities for advancements in cell and gene therapies, positioning them as crucial players in addressing the complexities of cancer and improving patient outcomes.
Opportunities: Approval of cell and gene therapies by regulatory agencies is expected to pave the way for market growth in the upcoming years.
The approval of cell and gene therapies by regulatory agencies represents a pivotal milestone, unlocking lucrative opportunities for market players in the pharmaceutical and biotechnology sectors. This validation from regulatory bodies not only signifies the safety and efficacy of these innovative therapies but also opens the door to a rapidly expanding market. In response to the growing significance of cell and gene therapies, pharmaceutical and biotechnology companies are actively engaging in strategic collaborations. These collaborations are designed to expedite the research, development, and commercialization processes, ultimately leading to an enhanced market presence, increased revenue, and a larger market share.
Strategic collaborations within the industry involve partnerships between different stakeholders, such as pharmaceutical companies, biotech firms, research institutions, and sometimes regulatory bodies. These collaborations leverage the unique strengths and expertise of each participant, fostering a synergistic approach to advancing cell and gene therapies.
Furthermore, the combined efforts of multiple entities contribute to a more comprehensive understanding of the intricacies involved in cell and gene therapy development, paving the way for breakthrough innovations. Overall, the approval of cell and gene therapies and the subsequent strategic collaborations reflect a dynamic and collaborative ecosystem within the pharmaceutical and biotechnology industries. As these therapies continue to revolutionize medical treatment, the strategic partnerships forged today will play a crucial role in shaping the future landscape of regenerative medicine and personalized healthcare.
COVID IMPACT:
The impact of the COVID-19 pandemic has been deeply felt across various facets of global society, and the realm of cell and gene therapy (CGT) has not been spared from its effects. The unprecedented scale and severity of the pandemic have triggered disturbances in social, economic, and political spheres worldwide. In this context, the CGT sector, which has traditionally grappled with inherent complexities in its supply chain, production processes, and logistical operations, now faces an added layer of disruption due to the challenges posed by the COVID-19 epidemic. The global CGT sector is intricately linked to a sophisticated and interdependent supply chain, relying on a range of materials such as specialized reagents, vectors, and other crucial components essential for the development of therapeutic interventions. The pandemic has given rise to disruptions in the production and distribution of these indispensable materials, subsequently impacting the timelines and progression of ongoing CGT projects. As the sector navigates these challenges, stakeholders are compelled to adapt swiftly, exploring alternative strategies for supply chain management, leveraging digital technologies for remote monitoring of trials, and seeking innovative solutions to ensure the continuous advancement of promising therapies despite the hurdles imposed by the pandemic.
SEGMENTATION ANALYSIS:
The consumable segment is anticipated to grow significantly during the forecast period.
In the 2022 consumables segment emerged as the primary focus within the product classification. This prevalence can be ascribed to various factors that shape the biomanufacturing landscape. In contrast to equipment, which generally boasts a shelf life of five to seven years, and software solutions that involve a one-time investment coupled with yearly maintenance costs, consumables serve as essential components required more frequently and in larger volumes for the production of cell and gene therapies. Consumables encompass a diverse array of materials, including specialized reagents, growth media, cell culture media, filtration systems, and other vital components pivotal for the biomanufacturing processes integral to cell and gene therapies. Owing to the recurrent and substantial demand for these consumables throughout the production cycle, their necessity tends to surpass that of equipment or software solutions.
The consumables segment plays a critical role in maintaining optimal conditions for cell growth, gene manipulation, and other crucial steps in the biomanufacturing process. The consistent and high-quality supply of consumables is imperative for the intricate protocols involved in cell and gene therapy production. Consequently, the dominance of the consumables segment underscores its significance within the biomanufacturing ecosystem, contributing substantially to the overall advancements and progress in the field of cell and gene therapy.
REGIONAL ANALYSIS:
The North American region is set to witness significant growth during the forecast period.
The North America market for cell and gene therapy biomanufacturing is poised to secure the leading market share in terms of revenue in the foreseeable future. This prominence is attributed to the region's increasing engagement in gene and cell therapy research and product development, along with a substantial presence of contract development businesses. Additionally, domestic companies are expanding their manufacturing operations within the region.
COMPETITIVE ANALYSIS
The global cell and gene therapy biomanufacturing market is reasonably competitive with mergers, acquisitions, and product launches. See some of the major key players in the market.
Sartorius AG (Sartorius Stedim Biotech S.A.)
In January 2023, Sartorius AG had collaborated with Roosterbio Inc. to advance its downstream purification processes for the development of exosomes.
AllogeneTherapeutics
In January 2022, AllogeneTherapeutics Inc had partnered with AntionBiosciences Inc. for Antion's miRNA technology (miCAR) to advance multiplex gene silencing as an additional tool in the development of next-generation allogeneic CAR T products.
Becton, Dickinson and Company
Endress+Hauser Group Services AG (Analytik Jena GmbH)
Danaher Corporation
Bio-Rad Laboratories, Inc.
Bio-Techne Corporation
General Electric Company (G.E. Healthcare)
Getinge AB
Infors AG
Lonza Group Ltd
Merck KGaA
Miltenyi Biotec B.V. & Co. KG
PIERRE GUERIN
Thermo Fisher Scientific Inc.
SCOPE OF THE REPORT
By Product Type
Consumables
Equipment
Software Solutions
By Usage
Commercial-Stage Manufacturing
Research-Stage Manufacturing
By End Users
Life Science Companies
Contract Research Organizations (CROs)
Contract Manufacturing Organizations (CMOs)
Cell Banks
By Region
North America (the United States & Canada)
Europe (Germany, UK, France, Spain, Italy, and the Rest of Europe)
Asia Pacific (China, Japan, India, and Rest of Asia Pacific)
Rest of the World (the Middle East & Africa, and Latin America)
KEY REASONS TO PURCHASE THIS REPORT
It provides a technological development map over time to understand the industry’s growth rate and indicates how the cell and gene therapy biomanufacturing market is evolving.
The report offers a dynamic method to various factors that drive or restrain the growth of the market and specifies which cell and gene therapy biomanufacturing submarket will be the main driver of the overall market from 2024 to 2032.
It renders a definite analysis of changing competitive dynamics and stipulates the leading players and what are their prospects over the forecast period.
It builds a nine-year estimate based on how the market is predicted to grow and shows what will market shares of the global region change by 2032 and which country will lead the market in 2032.
The global cell and gene therapy biomanufacturing market is projected to grow significantly, registering a CAGR of 11.3% during the forecast period (2024 – 2032).
Cell and gene therapy biomanufacturing involves the creation of therapeutic products through the manipulation of cells or genes, addressing various diseases. In cell therapy, live and functional cells are administered to patients to restore, repair, or enhance damaged tissues or organs. Conversely, gene therapy focuses on altering genetic material within a patient's cells to prevent or treat diseases. The biomanufacturing process for cell and gene therapies is intricate and highly regulated, intending to produce these advanced therapeutic products consistently and safely at a scale suitable for clinical and commercial applications. The initial step includes isolating cells from the patient or another source, followed by their expansion in a controlled culture environment. This cultivation phase aims to provide optimal conditions for cell growth while preserving the desired characteristics of the therapeutic cells. The overall objective is to adhere to rigorous quality control measures throughout the biomanufacturing process, ensuring the reliability, safety, and effectiveness of the final cell and gene therapies. The field of cell and gene therapy biomanufacturing continues to evolve, integrating advances in automation, process optimization, and standardization to enhance efficiency and scalability, bringing these innovative therapies closer to widespread clinical implementation.
MARKET OVERVIEW:
Driver: Increasing cancer diseases worldwide is expected to boost the market growth.
The increasing prevalence of cancer and other targeted diseases, coupled with rising research and development investments in pharmaceutical companies, is propelling the expansion of the market. A revised version of GLOBOCAN 2020 by the International Agency for Research on Cancer (IARC) indicates a global cancer burden of 19.3 million cases and 10 million cancer-related deaths in 2020. A recent study predicts that over the next five years, more than 50 million people will be diagnosed with cancer. Factors such as aging populations and socioeconomic risk factors are significant contributors to the rising incidence of cancer worldwide. Notably, breast cancer represents one in every four cancers diagnosed in women globally, surpassing lung cancer as the most commonly diagnosed cancer worldwide, particularly prevalent in low- and middle-income nations.
Given the complexity of cancer, cell and gene therapy emerges as a promising field for cancer treatment. Various gene therapy treatment approaches, including immunotherapy, gene transfer, and oncolytic virotherapy, offer innovative solutions. As the incidence of cancer continues to rise, the reliance on gene therapy is expected to grow, thereby stimulating market growth. The evolving landscape of cancer treatment presents substantial opportunities for advancements in cell and gene therapies, positioning them as crucial players in addressing the complexities of cancer and improving patient outcomes.
Opportunities: Approval of cell and gene therapies by regulatory agencies is expected to pave the way for market growth in the upcoming years.
The approval of cell and gene therapies by regulatory agencies represents a pivotal milestone, unlocking lucrative opportunities for market players in the pharmaceutical and biotechnology sectors. This validation from regulatory bodies not only signifies the safety and efficacy of these innovative therapies but also opens the door to a rapidly expanding market. In response to the growing significance of cell and gene therapies, pharmaceutical and biotechnology companies are actively engaging in strategic collaborations. These collaborations are designed to expedite the research, development, and commercialization processes, ultimately leading to an enhanced market presence, increased revenue, and a larger market share.
Strategic collaborations within the industry involve partnerships between different stakeholders, such as pharmaceutical companies, biotech firms, research institutions, and sometimes regulatory bodies. These collaborations leverage the unique strengths and expertise of each participant, fostering a synergistic approach to advancing cell and gene therapies.
Furthermore, the combined efforts of multiple entities contribute to a more comprehensive understanding of the intricacies involved in cell and gene therapy development, paving the way for breakthrough innovations. Overall, the approval of cell and gene therapies and the subsequent strategic collaborations reflect a dynamic and collaborative ecosystem within the pharmaceutical and biotechnology industries. As these therapies continue to revolutionize medical treatment, the strategic partnerships forged today will play a crucial role in shaping the future landscape of regenerative medicine and personalized healthcare.
COVID IMPACT:
The impact of the COVID-19 pandemic has been deeply felt across various facets of global society, and the realm of cell and gene therapy (CGT) has not been spared from its effects. The unprecedented scale and severity of the pandemic have triggered disturbances in social, economic, and political spheres worldwide. In this context, the CGT sector, which has traditionally grappled with inherent complexities in its supply chain, production processes, and logistical operations, now faces an added layer of disruption due to the challenges posed by the COVID-19 epidemic. The global CGT sector is intricately linked to a sophisticated and interdependent supply chain, relying on a range of materials such as specialized reagents, vectors, and other crucial components essential for the development of therapeutic interventions. The pandemic has given rise to disruptions in the production and distribution of these indispensable materials, subsequently impacting the timelines and progression of ongoing CGT projects. As the sector navigates these challenges, stakeholders are compelled to adapt swiftly, exploring alternative strategies for supply chain management, leveraging digital technologies for remote monitoring of trials, and seeking innovative solutions to ensure the continuous advancement of promising therapies despite the hurdles imposed by the pandemic.
SEGMENTATION ANALYSIS:
The consumable segment is anticipated to grow significantly during the forecast period.
In the 2022 consumables segment emerged as the primary focus within the product classification. This prevalence can be ascribed to various factors that shape the biomanufacturing landscape. In contrast to equipment, which generally boasts a shelf life of five to seven years, and software solutions that involve a one-time investment coupled with yearly maintenance costs, consumables serve as essential components required more frequently and in larger volumes for the production of cell and gene therapies. Consumables encompass a diverse array of materials, including specialized reagents, growth media, cell culture media, filtration systems, and other vital components pivotal for the biomanufacturing processes integral to cell and gene therapies. Owing to the recurrent and substantial demand for these consumables throughout the production cycle, their necessity tends to surpass that of equipment or software solutions.
The consumables segment plays a critical role in maintaining optimal conditions for cell growth, gene manipulation, and other crucial steps in the biomanufacturing process. The consistent and high-quality supply of consumables is imperative for the intricate protocols involved in cell and gene therapy production. Consequently, the dominance of the consumables segment underscores its significance within the biomanufacturing ecosystem, contributing substantially to the overall advancements and progress in the field of cell and gene therapy.
REGIONAL ANALYSIS:
The North American region is set to witness significant growth during the forecast period.
The North America market for cell and gene therapy biomanufacturing is poised to secure the leading market share in terms of revenue in the foreseeable future. This prominence is attributed to the region's increasing engagement in gene and cell therapy research and product development, along with a substantial presence of contract development businesses. Additionally, domestic companies are expanding their manufacturing operations within the region.
COMPETITIVE ANALYSIS
The global cell and gene therapy biomanufacturing market is reasonably competitive with mergers, acquisitions, and product launches. See some of the major key players in the market.
Sartorius AG (Sartorius Stedim Biotech S.A.)
In January 2023, Sartorius AG had collaborated with Roosterbio Inc. to advance its downstream purification processes for the development of exosomes.
AllogeneTherapeutics
In January 2022, AllogeneTherapeutics Inc had partnered with AntionBiosciences Inc. for Antion's miRNA technology (miCAR) to advance multiplex gene silencing as an additional tool in the development of next-generation allogeneic CAR T products.
Becton, Dickinson and Company
Endress+Hauser Group Services AG (Analytik Jena GmbH)
Danaher Corporation
Bio-Rad Laboratories, Inc.
Bio-Techne Corporation
General Electric Company (G.E. Healthcare)
Getinge AB
Infors AG
Lonza Group Ltd
Merck KGaA
Miltenyi Biotec B.V. & Co. KG
PIERRE GUERIN
Thermo Fisher Scientific Inc.
SCOPE OF THE REPORT
By Product Type
Consumables
Equipment
Software Solutions
By Usage
Commercial-Stage Manufacturing
Research-Stage Manufacturing
By End Users
Life Science Companies
Contract Research Organizations (CROs)
Contract Manufacturing Organizations (CMOs)
Cell Banks
By Region
North America (the United States & Canada)
Europe (Germany, UK, France, Spain, Italy, and the Rest of Europe)
Asia Pacific (China, Japan, India, and Rest of Asia Pacific)
Rest of the World (the Middle East & Africa, and Latin America)
KEY REASONS TO PURCHASE THIS REPORT
It provides a technological development map over time to understand the industry’s growth rate and indicates how the cell and gene therapy biomanufacturing market is evolving.
The report offers a dynamic method to various factors that drive or restrain the growth of the market and specifies which cell and gene therapy biomanufacturing submarket will be the main driver of the overall market from 2024 to 2032.
It renders a definite analysis of changing competitive dynamics and stipulates the leading players and what are their prospects over the forecast period.
It builds a nine-year estimate based on how the market is predicted to grow and shows what will market shares of the global region change by 2032 and which country will lead the market in 2032.
Table of Contents
185 Pages
- 1. Executive Summary
- 1.1. Market Snapshot
- 1.2. Regional Analysis
- 1.3. Segment Analysis
- 2. Overview And Scope
- 2.1. Market Vision
- 2.1.1. Market Definition
- 2.2. Market Segmentation
- 3. Global Cell And Gene Therapy Biomanufacturing Market Overview By Region: 2019 Vs 2023 Vs 2032
- 3.1. Global Cell And Gene Therapy Biomanufacturing Market Size By Regions (2019-2023) (Usd Million)
- 3.1.1. North America Cell And Gene Therapy Biomanufacturing Market Size By Country (2019-2023) (Usd Million)
- 3.1.2. Europe Cell And Gene Therapy Biomanufacturing Market Size By Country (2019-2023) (Usd Million)
- 3.1.3. Asia Pacific America Cell And Gene Therapy Biomanufacturing Market Size By Country (2019-2023) (Usd Million)
- 3.1.4. Rest Of The World Cell And Gene Therapy Biomanufacturing Market Size By Country (2019-2023) (Usd Million)
- 3.2. Global Cell And Gene Therapy Biomanufacturing Market Size By Regions (2024-2032) (Usd Million)
- 3.2.1. North America Cell And Gene Therapy Biomanufacturing Market Size By Country (2024-2032) (Usd Million)
- 3.2.2. Europe Cell And Gene Therapy Biomanufacturing Market Size By Country (2024-2032) (Usd Million)
- 3.2.3. Asia Pacific Cell And Gene Therapy Biomanufacturing Market Size By Country (2024-2032) (Usd Million)
- 3.2.4. Rest Of The World Cell And Gene Therapy Biomanufacturing Market Size By Country (2024-2032) (Usd Million)
- 4. Global Farm Management Software Market Dynamics
- 4.1. Market Overview
- 4.1.1. Market Drivers
- 4.1.2. Market Restraints/ Challenges Analysis
- 4.1.3. Market Opportunities
- 4.2. Pestle Analysis
- 4.3. Porter’s Five Forces Model
- 4.3.1. Bargaining Power Of Suppliers
- 4.3.2. Bargaining Power Of Buyers
- 4.3.3. The Threat Of New Entrants
- 4.3.4. Threat Of Substitutes
- 4.3.5. Intensity Of Rivalry
- 4.4. Value Chain Analysis/Supply Chain Analysis
- 4.5. Covid-19 Impact Analysis On Global Cell And Gene Therapy Biomanufacturing Market
- ** In – Depth Qualitative Analysis Will Be Provided In The Final Report Subject To Market
- 5. Global Cell And Gene Therapy Biomanufacturing Market, By Type
- 5.1. Overview
- 5.2. Global Cell And Gene Therapy Biomanufacturing Market Size By Product Type
- 5.3. Key Findings For Cell And Gene Therapy Biomanufacturing Market - By Product Type
- 5.3.1. Local/Web-based
- 5.3.2. Cloud-based
- 6. Global Cell And Gene Therapy Biomanufacturing Market, By Service
- 6.1. Overview
- 6.2. Key Findings For Cell And Gene Therapy Biomanufacturing Market - By Usage
- 6.2.1. Managed Service
- 6.2.2. Professional Service
- 6.2.3. Connectivity Service
- 7. Global Cell And Gene Therapy Biomanufacturing Marke, By Application
- 7.1. Overview
- 7.2. Key Findings For Cell And Gene Therapy Biomanufacturing Market - By End Users
- 7.2.1. Precision Farming
- 7.2.2. Livestock Monitoring
- 7.2.3. Smart Greenhouse
- 7.2.4. Aquaculture
- 7.2.5. Other Applications
- 8. Global Cell And Gene Therapy Biomanufacturing Market, By Region
- 8.1. Overview
- 8.2. Key Findings For Cell And Gene Therapy Biomanufacturing Market- By Region
- 8.3. Global Cell And Gene Therapy Biomanufacturing Market, By Product Type
- 8.4. Global Cell And Gene Therapy Biomanufacturing Market, By Usage
- 8.5. Global Cell And Gene Therapy Biomanufacturing Market, By End Users
- 9. Global Cell And Gene Therapy Biomanufacturing Market- North America
- 9.1. Overview
- 9.2. North America Cell And Gene Therapy Biomanufacturing Market Size (2019 - 2032) (Usd Million)
- 9.3. North America Cell And Gene Therapy Biomanufacturing Market, By Product Type
- 9.4. North America Cell And Gene Therapy Biomanufacturing Market, By Usage
- 9.5. North America Cell And Gene Therapy Biomanufacturing Market, By End Users
- 9.6. North America Cell And Gene Therapy Biomanufacturing Market Size By Countries
- 9.6.1. United States
- 9.6.2. Canada
- 10. Global Cell And Gene Therapy Biomanufacturing Market- Europe
- 10.1. Overview
- 10.2. Europe Cell And Gene Therapy Biomanufacturing Market Size (2019 - 2032) (Usd Million)
- 10.3. Europe Cell And Gene Therapy Biomanufacturing Market, By Product Type
- 10.4. Europe Cell And Gene Therapy Biomanufacturing Market, By Usage
- 10.5. Europe Cell And Gene Therapy Biomanufacturing Market, By End Users
- 10.6. Europe Cell And Gene Therapy Biomanufacturing Market Size By Countries
- 10.6.1. Germany
- 10.6.2. Uk
- 10.6.3. France
- 10.6.4. Spain
- 10.6.5. Italy
- 10.6.6. Rest Of Europe
- 11. Global Cell And Gene Therapy Biomanufacturing Market - Asia Pacific
- 11.1. Overview
- 11.2. Asia Pacific Cell And Gene Therapy Biomanufacturing Market Size (2019 - 2032) (Usd Million)
- 11.3. Asia Pacific Cell And Gene Therapy Biomanufacturing Market, By Product Type
- 11.4. Asia Pacific Cell And Gene Therapy Biomanufacturing Market, By Usage
- 11.5. Asia Pacific Cell And Gene Therapy Biomanufacturing Market, By End Users
- 11.6. Asia Pacific Cell And Gene Therapy Biomanufacturing Market Size By Countries
- 11.6.1. China
- 11.6.2. Japan
- 11.6.3. India
- 11.6.4. Rest Of Asia Pacific
- 12. Global Cell And Gene Therapy Biomanufacturing Market- Rest Of World
- 12.1. Overview
- 12.2. Rest Of World Cell And Gene Therapy Biomanufacturing Market Size (2019 - 2032) (Usd Million)
- 12.3. Rest Of World Cell And Gene Therapy Biomanufacturing Market, By Product Type
- 12.4. Rest Of World Cell And Gene Therapy Biomanufacturing Market, By Usage
- 12.5. Rest Of World Cell And Gene Therapy Biomanufacturing Market, By End Users
- 12.6. Rest Of World Cell And Gene Therapy Biomanufacturing Market Size By Regions
- 12.6.1. Middle East & Africa
- 12.6.2. Latin America
- 13. Global Cell And Gene Therapy Biomanufacturing Market- Competitive Landscape
- 13.1. Key Strategies Adopted By The Leading Players
- 13.2. Recent Developments
- 13.2.1. Investments & Expansions
- 13.2.2. New End-user Launches
- 13.2.3. Mergers & Acquisitions
- 13.2.4. Agreements, Joint Ventures, And Partnerships
- 14. Global Cell And Gene Therapy Biomanufacturing Market- Company Profiles
- 14.1. Trimble Inc.
- 14.1.1. Company Overview
- 14.1.2. Financial Overview
- 14.1.3. Product Offered
- 14.1.4. Key Developments
- 14.2. Becton, Dickinson And Company
- 14.3. Endress+Hauser Group Services Ag (Analytik Jena Gmbh)
- 14.4. Danaher Corporation
- 14.5. Bio-rad Laboratories, Inc.
- 14.6. Bio-techne Corporation
- 14.7. General Electric Company (G.E. Healthcare)
- 14.8. Getinge Ab
- 14.9. Infors Ag
- 14.10. Lonza Group Ltd
- 14.11. Merck Kgaa
- 14.12. Miltenyi Biotec B.V. & Co. Kg
- 14.13. Pierre Guerin
- 14.14. Sartorius Ag (Sartorius Stedim Biotech S.A.)
- 14.15. Thermo Fisher Scientific Inc.
- 15. Our Research Methodology
- 15.1. Data Triangulation
- 15.2. Data Sources
- 15.2.1. Secondary Sources
- 15.2.2. Primary Sources
- 15.3. Assumptions/ Limitations For The Study
- 15.4. Research & Forecasting Methodology
- 16. Appendix
- 16.1. Disclaimer
- 16.2. Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
